Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Edwards Lifesciences Corporation (EW : NYSE)
 
 • Company Description   
Edwards Lifesciences Corporation deals in products and technologies aimed at treating advanced cardiovascular diseases, especially structural heart disease in critically ill patients. The company is the world's leading manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. Edwards is also a leading player in hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The company's products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart, and Critical Care.

Number of Employees: 15,700

 
 • Price / Volume Information   
Yesterday's Closing Price: $94.32 Daily Weekly Monthly
20 Day Moving Average: 3,255,345 shares
Shares Outstanding: 621.75 (millions)
Market Capitalization: $58,643.65 (millions)
Beta: 1.16
52 Week High: $131.73
52 Week Low: $91.52
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -24.91% -15.44%
12 Week -13.97% -5.43%
Year To Date -27.19% -10.99%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
ONE EDWARDS WAY
-
IRVINE,CA 92614
USA
ph: 949-250-2500
fax: 949-250-2525
investor_relations@edwards.com http://www.edwards.com
 
 • General Corporate Information   
Officers
Michael A. Mussallem - Chief Executive Officer and Chairman
Scott B. Ullem - Corporate Vice President and Chief Financial Offic
Robert W.A. Sellers - Vice President and Corporate Controller
Kieran T. Gallahue - Director
Leslie S. Heisz - Director

Peer Information
Edwards Lifesciences Corporation (ABMD)
Edwards Lifesciences Corporation (DMDS)
Edwards Lifesciences Corporation (CPWY.)
Edwards Lifesciences Corporation (EQUR)
Edwards Lifesciences Corporation (ECIA)
Edwards Lifesciences Corporation (FMS)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED INSTRUMENTS
Sector: Medical
CUSIP: 28176E108
SIC: 3842
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 621.75
Most Recent Split Date: 6.00 (3.00:1)
Beta: 1.16
Market Capitalization: $58,643.65 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.64 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $2.56 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 11.00 Change In Payout Ratio: 0.00
Estmated Long-Term EPS Growth Rate: 12.91% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 36.80
Trailing 12 Months: 41.19
PEG Ratio: 2.85
Price Ratios
Price/Book: 10.03
Price/Cash Flow: 38.27
Price / Sales: 10.95
EPS Growth
vs. Year Ago Period: 11.11%
vs. Previous Quarter: 17.65%
Sales Growth
vs. Year Ago Period: 10.24%
vs. Previous Quarter: 0.86%
ROE
03/31/22 - 25.80
12/31/21 - 26.53
09/30/21 - 28.13
ROA
03/31/22 - 17.61
12/31/21 - 17.81
09/30/21 - 18.50
Current Ratio
03/31/22 - 3.41
12/31/21 - 3.08
09/30/21 - 3.64
Quick Ratio
03/31/22 - 2.64
12/31/21 - 2.38
09/30/21 - 2.87
Operating Margin
03/31/22 - 26.91
12/31/21 - 26.83
09/30/21 - 27.48
Net Margin
03/31/22 - 28.72
12/31/21 - 28.73
09/30/21 - 29.00
Pre-Tax Margin
03/31/22 - 32.65
12/31/21 - 32.53
09/30/21 - 33.01
Book Value
03/31/22 - 9.40
12/31/21 - 9.35
09/30/21 - 8.88
Inventory Turnover
03/31/22 - 1.70
12/31/21 - 1.67
09/30/21 - 1.61
Debt-to-Equity
03/31/22 - 0.10
12/31/21 - 0.10
09/30/21 - 0.11
Debt-to-Capital
03/31/22 - 9.25
12/31/21 - 9.26
09/30/21 - 9.70
 

Powered by Zacks Investment Research ©